K082594

## 510(k) Summary

Submitter Name:

Remedent NV

Submitter Address:

Xavier de Cocklaan 42 Deurle, BELGIUM B-9831

Phone Number:

603 369 3550

Fax Number:

603 369 3562

Contact Person:

William Greenrose

Date Prepared:

02 September 2008

Device Trade Name:

Remesense

Common Name

Tooth Desensitizer

Classification Name,

Cavity Varnish

Number &

872.5260

Product Code:

LBH

Predicate Devices:

K061438 - UltraEZ, K041680 - Orajel, K983477 - SuperSeal, K073061 -

Provident (details in table below)

Device Description and Statement of Intended Use

<u>Device Description</u>: Remesense consists of a tray and impregnated foam strips. The Remesense foam strips are thin flexible foam strips, impregnated with a desensitizing liquid. These strips are designed to relieve dental (hyper) sensitivity by patient application to the affected tooth (teeth). The impregnated foam strips are held in place with trays.

Statement of Intended Use: Remesense is intended for the local management of dental sensitivity by patient application of foam strips

impregnated with desensitizing gel.

Summary of Technological Characteristics Potassium oxalate breaks down into potassium and oxalic acid. The oxalic acid reacts with calcium ions to form calcium-oxalate crystals. These crystals block the dentin tubules, thereby alleviating dental

sensitivity. Blockage of dentin tubules is commonly used by many tooth sensitivity agents to reduce tooth sensitivity, and potassium oxalate is a

common material used to block dentin tubules.

Submitter: Remedent

Remesense Premarket Notification: Traditional 510(k)

K082594

Conclusion

The information discussed above demonstrates that the Remesense device is substantially equivalent to the predicate devices

Declarations

- This summary includes only information that is also covered in the body of the 510(k).
- This summary does not contain any puffery or unsubstantiated labeling claims.
- This summary does not contain any raw data, i.e., contains only summary data.
- This summary does not contain any trade secret or confidential commercial information.
- o This summary does not contain any patient identification information.

## **Summary of Technical Characteristics**

Feature	Remesense	UltraEZ	Orajel	Superseal	Provident
510(k) Number	TBD	K061438	K041680	K983477	K073061
Manufacturer	Remedent	Ultradent Products, Inc.	DEL Pharmaceuticals, Inc.	Phoenix Dental, Inc.	Coll Partners, Ltd.
Classification # & Product Code	872.3260 LBH	872.3260 LBH	872.3200 KLE	872.3250 EJK	872.3260 LBH
Classification Name	Cavity Varnish	Cavity Varnish	Tooth bonding resin agent	Calcium hydroxide cavity liner	Cavity Varnish
Common Name	Tooth Desensitizer	Tooth Desensitizer	Tooth Desensitizer	Tooth Desensitizer	Tooth Desensitizer
Indications for Use	Tooth Desensitizer	Provides a film like varnish for exposed teeth sealing dentinal tubules of over exposed dentin or other exposed areas where postoperative or other dentin sensitivity is a concern.	Tooth Desensitizer	A potassium oxalate based film forming acid resistant liner and desensitizer that is indicated for application prior to restoration of exposed dentin.	A fluoride containing varnish system intended for use as a desensitizing agent on the surface areas of hypersensitive or potentially sensitive teeth.
Mode of Action	Tubule Occlusion	Tubule Occlusion	Tubule Occlusion	Tubule Occlusion	Tubule Occlusion
Material Composition	Potassium Oxalate	KNO3 and KF	2-hydroxyethyl methacrylate	Potassium Oxalate	KF
Application	Tray/Kit/Gel	Gel	Liquid w/Swab	Gel	Tray/Kit/Gel
Rx/OTC	Rx	Rx	Rx	Rx	Rx





MAR 1 9 2009

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Remedent NV C/o Mr. William Greenrose President Qserve America, Incorporated 220 River Road Claremont, New Hampshire 03743-5567

Re: K082594

Trade/Device Name: Remesense

Regulation Number: 21 CFR 872.3260 Regulation Name: Cavity Varnish

Regulatory Class: II Product Code: LBH Dated: March 12, 2009 Received: March 17, 2009

## Dear Mr. Greenrose:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Ginette Y. Michaud, M.D.

Acting Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## 4.1 Indications for Use Statement

510(k) Number (if known):

K082594

**Device Name:** 

Remesense

Indications for Use:

Remesense is indicated for use as a tooth desensitizer.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH; Office of Device Evaluation (ODE)

Prescription Use

Χ

OR

Over-The-Counter Use

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

(Division Sign-Off)

Division of Anesthesiology, General Hospital Infection Control, Dental Devices

510(k) Number: